A Single-arm Open Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

  • STATUS
    Recruiting
  • End date
    Dec 30, 2022
  • participants needed
    53
  • sponsor
    Sun Yat-sen University
Updated on 24 March 2021
cancer
monoclonal antibodies
measurable disease
metastasis
neutrophil count
ewing's sarcoma
angiosarcoma
desmoplastic
fibrosarcoma
soft tissue sarcoma
liposarcoma
synovial sarcoma
undifferentiated pleomorphic sarcoma
leiomyosarcoma
gastrointestinal stromal tumor
advanced soft tissue sarcoma
stromal tumor
epithelioid sarcoma
advanced sarcoma
mpnst
malignant peripheral nerve sheath tumor

Summary

Soft tissue sarcoma is a relatively rare malignant tumor with an incidence of about 1-2/100,000. The best way to obtain evidence-based medical evidence is to participate in clinical trials with new drugs (especially targeted drugs and immunotherapy). Chidamide, an oral subtype-selective histone deacetylase inhibitor monotherapy was effective on the patients with hematological tumors by inhibiting HDAC activity and other ways, showing good anti-tumor activity. Histone deacetylase inhibitors (HDACi) may also reverse drug resistance or inefficiency of immunoassay inhibitors, and combination therapy has shown preliminary efficacy in a variety of tumors.Because of the poor prognosis of advanced soft tissue sarcoma, there is no standard second-line treatment. Therefore, we think it is necessary to explore the feasibility of combination of chidamide and Toripalimab monoclonal antibody in advanced, refractory and progressive soft tissue sarcoma after failure of standard treatment, and look forward to further improving the efficacy of soft tissue sarcoma.

Description

Histone deacetylase inhibitor (HDACI) can inhibit many kinds of hematological tumors by inhibiting HDAC activity and other ways, showing good anti-tumor activity. Chidamide is a new chemical structure benzamide HDAC inhibitor developed independently in China. It has the selectivity of HDAC subtypes and unique efficacy. In a phase II clinical study of Chidamide in the treatment of peripheral T-cell lymphoma in China in 2009, 79 patients with recurrent or refractory lymphoma had ORR of 27.9%. The 2016 edition of the Chinese Expert Consensus on Chidamide in the Treatment of PTCL discussed in detail the treatment of Chidamide alone or in combination with other drugs.

The representative drug of immunological checkpoint inhibitors is programmed death 1 (PD-1/PD-L1). PD-1/PD-L1 immunotherapy activates the body's own immune system to attack cancer cells by blocking the PD-1/PD-L1 pathway with drugs. Immunotherapy show its long-term control of cancer and its effectiveness in a variety of cancers.

In a multicenter phase II clinical trial, 80 patients with bone and soft tissue sarcoma were treated with single drug of PD-1 antibody Pembrolizumab. The results showed that all the patients with soft tissue sarcoma achieved therapeutic effect were undifferentiated pleomorphic sarcoma and liposarcoma. The overall objective remission rate was 18% (7/40), suggesting that Pembrolizumab alone does not fully activate suppressed T cells, and may need to be combined to improve the efficacy.

Recent studies have shown that combination of epigenetic regulators, such as histone deacetylase inhibitors (HDACi), can overcome some major drug resistance constraints and ensure patient safety. Pre-clinical data based on mouse models strongly support the feasibility and effectiveness of combination therapy. In vitro and in vivo studies, combined use of pan- or class I selective HDACi can benefit further. Chidamide is mainly targeted at subtypes 1, 2, 3 and 10 of HDAC class I and class II B. It has a regulatory effect on the abnormal epigenetic function of tumors. By inhibiting the related HDAC subtypes to increase the acetylation level of chromatin histone, chromatin remodeling is initiated, which changes the gene expression of multiple signal transduction pathways (i.e. epigenetic changes), thereby inhibiting the cell cycle of tumors, inducing apoptosis of tumors, and having overall regulatory activity on cellular immunity. Induction and enhancement of natural killer cells (NK) and antigen-specific cytotoxic T cells (CTL) mediated tumor killing. Chidamide can also enhance the mechanism of dendritic cells presenting and maturing tumor antigens, inhibiting regulatory T cells (Treg) and MDSC cells, and promote the anti-tumor immune function through regulating the micro-environment of tumor immunosuppression.

Because of the poor prognosis of advanced soft tissue sarcoma, there is no standard treatment for second-line treatment. Therefore, we think it is necessary to explore the feasibility of combination of chidamide and Toripalimab in advanced, refractory and progressive soft tissue sarcoma after failure of standard treatment, and look forward to further improving the efficacy of soft tissue sarcoma.

Details
Condition Connective and Soft Tissue Neoplasm, Sarcoma, All Solid Tumors, Solid Tumors, Sarcoma (Pediatric), Soft Tissue Sarcoma, sarcomas, soft tissue sarcomas
Treatment chidamide and toripalimab
Clinical Study IdentifierNCT04025931
SponsorSun Yat-sen University
Last Modified on24 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Gender: Male or Female
Do you have any of these conditions: Sarcoma or Connective and Soft Tissue Neoplasm or Sarcoma (Pediatric) or Soft Tissue Sarcoma or All Solid Tumors or Solid Tumors?
Do you have any of these conditions: Sarcoma (Pediatric) or All Solid Tumors or soft tissue sarcomas or Solid Tumors or Connective and Soft Tissue Neoplasm or Soft Tissue Sarcoma or Sarco...?
Do you have any of these conditions: Sarcoma (Pediatric) or All Solid Tumors or Solid Tumors or soft tissue sarcomas or sarcomas or Sarcoma or Connective and Soft Tissue Neoplasm or Soft ...?
Do you have any of these conditions: Solid Tumors or Sarcoma (Pediatric) or soft tissue sarcomas or Sarcoma or sarcomas or All Solid Tumors or Soft Tissue Sarcoma or Connective and Soft T...?
Patients voluntarily participated in this study and signed the informed consent
The pathology diagnosed with at least one measurable lesion according to RECIST 1.1 standard. The pathology includes synovial sarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, liposarcoma, fibrosarcoma, clear cell sarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, rhabdomyosarcoma, dermatofibrosareoma promberans, ewing's sarcoma /primary neural ectoderm tumors, desmoplastic small round cell tumor, inflammatory myofibroblastic sarcoma, malignant solitary fibroma. Except for chondrosarcoma, osteosarcoma, malignant mesothelioma, alveolar soft tissue sarcoma, gastrointestinal stromal tumor
Advanced sarcoma patients with refractory or distant metastasis after failure of first-line standard therapy
18 ~ 70 years old; ECOG PS score: 0~1; Expected survival beyond 3 months; 5Adequate organ and bone marrow function, no serious hematopoietic dysfunction or heart, lung, liver, kidney, thyroid dysfunction and immune deficiency (no blood transfusion, granulocyte colony stimulating factor or other medical support was received within 14 days before the use of the research drug)
Major organs functions should meet the following standards within 7 days before
treatment
Blood routine examination standard (without blood transfusion within 14 days)
Hemoglobin (HB) 90g/L; The absolute value of neutrophils (ANC) 1.5109/L
Platelet (PLT) 80 109/L
Biochemical examination shall meet the following standards
Total bilirubin (TBIL) 1.5 times ULN (Upper Limit Of Normal); alanine
aminotransferase ALTand aspartate aminotransferase AST2.5 times ULN. If
accompanied by liver metastasis, ALT and AST5 times ULNSerum creatinineCr1.5
times ULN or creatinine clearance rate (CCr) 60ml/min Doppler ultrasound
evaluation: left ventricular ejection fraction (LVEF) normal low limit (50%)
\. Thyrotropin (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3)
were all within the normal range (+10%)
\. Women of reproductive age should agree to use contraceptives (such as
intrauterine devices, contraceptives or condoms) during and within 6 months
after the study; Negative serum or urine pregnancy test within 7 days prior to
study enrollment and must be non-lactating; 9. Men should agree to use
contraceptives during and within 6 months after the study period

Exclusion Criteria

Patients who have previously used chidamide or other histone deacetylase inhibitors
Previous treatment with immunological checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
Other malignancies that have occurred or are present at the same time within 5 years, except for cured cancers including carcinoma in situ of the cervix, non-melanoma skin cancer and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)]
Start the study of systemic anti-cancer therapy within 28 days before treatment, including chemotherapy, immunotherapy, biotherapy (cancer vaccine, cytokines, or growth factors that control cancer)
The patients received Chinese herbal medicine or Chinese patent medicine treatment within 7 days before the start of the study
Systemic anti-tumor therapy, including cytotoxic therapy, signal transduction inhibitors, and immunotherapy (or mitomycin C administration within 6 weeks before the treatment with the experimental drug), is planned within 4 weeks before enrollment or during the medication period of this study. In the first 4 weeks of enrollment, the patients were treated with field expanding radiotherapy (ef-rt) or the limited field radiotherapy designed to evaluate tumor lesions in the first 2 weeks of enrollment
Accompanied by pleural effusion or ascites, causing respiratory syndrome (CTCAE grade 2 dyspnea [grade 2 dyspnea refers to shortness of breath when there is a small amount of activity; it affects instrumental daily life activities])
Unrelieved toxic reactions caused by any previous treatment higher than CTCAE (4.1) level 1 or above, excluding hair loss
Patients with brain metastases with symptoms or with symptoms for less than 2 months
Patients with any severe and/or uncontrolled disease, including
)Patients with unsatisfactory blood pressure control (systolic blood pressure
mmHg, diastolic blood pressure 100 mmHg); 2)Patients with grade I or above
myocardial ischemia or myocardial infarction, arrhythmia (including QTC 480ms)
and grade II congestive heart failure (NYHA classification); 3)Active or
uncontrolled severe infection (CTCAE grade 2 infection); 4)Cirrhosis
decompensated liver disease, active hepatitis or chronic hepatitis require
antiviral treatment; 5) Renal failure requires hemodialysis or peritoneal
dialysis; 6) Have a history of immunodeficiency, including HIV positive or
other acquired or congenital immunodeficiency diseases, or have a history of
organ transplantation; 7)Poor control of diabetes mellitus (FBG) > 10mmol/L)
)Urine routine test indicated urine protein ++, and confirmed the 24-hour
urine protein quantitative > 1.0g; 9)Patients with seizures requiring
treatment
\. Received major surgical treatment, open biopsy or obvious traumatic
injury within 28 days before enrollment
\. Patients with any signs of bleeding constitution or medical history
regardless of the severity; Patients with any bleeding or bleeding event CTCAE
level 3 within 4 weeks before enrollment have unhealed wounds, ulcers or
fractures
\. Hyperactive/venous thrombosis events within 6 months, such as
cerebrovascular accidents (including temporary ischemic attack), deep venous
thrombosis and pulmonary embolism
\. Patients with active ulcer, intestinal perforation and intestinal
obstruction
\. Have a history of mental drug abuse and cannot quit or have mental
disorder
\. Participated in clinical trials of other anti-tumor drugs within 28 days
before enrollment
According to the judgment of the researcher, there are those who seriously
endanger the safety of patients or affect the patients' completion of the
study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note